$ARWR Christopher R. Anzalone, Arrowhead Pharmaceuticals, Inc. - CEO, President & Director said the following in the Monday earnings call - "There are now 5 TRiM-enabled candidates in the clinic, 3 of which are wholly owned and 2 are partnered. Over the next month, we plan to submit regulatory filings for 2 additional clinical candidates. And by the end of 2020, we intend to have 10 TRiM-enabled candidates in clinical studies targeting 4 different cell types. Further, we expect to be in 3 pivotal studies by the end of 2020. Let that all sink in for a moment. We believe this is a strikingly unique position for a company our size." I copied and pasted from the transcript this it is word for word what he said.
  • 7
  • 1